Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
18 Février 2025 - 2:02PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Annual Financial Report
18 February 2025
Annual Financial Report
AstraZeneca PLC (the Company) announced today the publication of
its Annual Report and Form 20-F Information 2024 (the Annual
Report).
A copy of the Annual Report will be submitted to the National
Storage Mechanism and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Annual Report is also available on the Company's
website www.astrazeneca.com.
The Annual Report will be dispatched to shareholders in due
course.
The Company's Annual General Meeting (AGM) will take place on 11
April 2025. The Notice of AGM and Shareholders' Circular will be
published and distributed to shareholders in due
course.
EXPLANATORY NOTE
For the purposes of complying with the Disclosure and Transparency
Rules, the Annual Report being submitted to the National Storage
Mechanism contains the following regulated information in unedited
form:
- the principal risks
and uncertainties facing the Company;
-
the Directors' responsibility statement made in
respect of the Financial Statements and Directors' Report contained
in the Annual Report; and
- a statement regarding related party
transactions.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca's innovative medicines are sold in more
than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For
details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
18 February 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (PK) (USOTC:AZNCF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025
AstraZeneca (PK) (USOTC:AZNCF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025
